Compare Novartis AG (NVS) vs Direxion NASDAQ 100 Equal Weighted Index Shares (QQQE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Direxion NASDAQ 100 Equal Weighted Index Shares — how do they compare? Novartis AG trades at $143.53 (market cap $268.57B), while Direxion NASDAQ 100 Equal Weighted Index Shares trades at $121.68 (market cap $1.45B). The key difference: Novartis AG is far larger — about 185.2× Direxion NASDAQ 100 Equal Weighted Index Shares's market cap, and Novartis AG pays a 3.31% dividend while Direxion NASDAQ 100 Equal Weighted Index Shares pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novartis AG for 82 Days and Direxion NASDAQ 100 Equal Weighted Index Shares for 47 Days on average.
| NVS | QQQE | |
|---|---|---|
Market Cap | $268.57B | $1.45B |
Volume | 1,532,573 | 323,568 |
Sector | Health | Broad Market / Factor |
52-Week High | $168.62 | $124.69 |
52-Week Low | $121.80 | $96.06 |
Typical Hold Time | 82 Days | 47 Days |
Enterprise Value | $309.89B | — |
Dividend Yield | 3.31% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) trades at $143.22, down 0.04% on the day, near the analyst consensus price target of $146. The stock shows mixed technical signals with a bearish moving average trend but neutral oscillators. Fundamentally, the company reported strong 2025 revenue of $56.67B and net income of $13.98B, with a robust net margin of 24.67%. Recent developments include a significant $7.8B licensing deal with China's Abogen for mRNA therapy, though this follows clinical setbacks in other drug programs.
The outlook is cautiously optimistic. The Abogen deal expands the pipeline in autoimmune diseases, a growth area, and analyst consensus leans Hold with a slight upside to the price target. Key risks include integration challenges from recent acquisitions, pipeline volatility after trial failures, and investor scrutiny over M&A strategy. Earnings momentum is mixed, with a recent beat in Q2 but a miss in Q1, requiring consistent execution to justify current valuations.
QQQE (Direxion NASDAQ-100 Equal Weighted Index ETF) trades at $121.58, down 0.25% on the day, with a bullish technical signal from moving averages while oscillators remain neutral. The ETF provides equal-weighted exposure to NASDAQ-100 companies, reducing technology concentration from 60% to 45% compared to market-cap weighted alternatives. Recent analysis suggests QQQE offers tactical advantages over QQQ for the next twelve months due to its equal-weight methodology.
The outlook for QQQE appears favorable as equal weighting provides diversification benefits amid potential tech sector volatility. Key risks include NASDAQ concentration and market sensitivity, but the ETF's structure offers balanced exposure to large-cap growth stocks. Technical support levels at $120-121 provide near-term downside protection.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Direxion NASDAQ 100 Equal Weighted Index Shares
QQQE is an ETF that seeks to track the performance of the NASDAQ-100 Equal Weighted Index. Unlike traditional market-capitalization-weighted indexes, this fund assigns equal weight to each of the 100 non-financial companies in the NASDAQ-100 and rebalances quarterly. This equal-weighting scheme reduces concentration risk in the largest technology companies and increases the fund's exposure to smaller-cap and mid-cap companies within the index, providing a differentiated growth profile.
Read more on QQQE →
